Evidence map›Paper›PMID 36290552›Full record

ArticleBioengineering (Basel, Switzerland)2022

Risk Factors Associated with Mortality in Hospitalized Patients with COVID-19 during the Omicron Wave in Brazil.

Marilaine Colnago, Giovana A Benvenuto, Wallace Casaca, Rogério G Negri, Eder G Fernandes, José A Cuminato

Open access · goldAbstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset.American journal of respiratory and critical care medicine · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Risk factors for death and illness severity in vaccinated versus unvaccinated COVID-2019 inpatients: a retrospective cohort study.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023
    Observational
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marilaine ColnagoInstitute of Chemistry, São Paulo State University (UNESP), Araraquara 14800-060, Brazil.ORCID 0000-0003-1599-491X
Giovana A BenvenutoFaculty of Science and Technology (FCT), São Paulo State University (UNESP), Presidente Prudente 19060-900, Brazil.ORCID 0000-0002-0531-1284
Wallace CasacaInstitute of Biosciences, Letters and Exact Sciences, São Paulo State University (UNESP), São José do Rio Preto 15054-000, Brazil.ORCID 0000-0002-1073-9939
Rogério G NegriScience and Technology Institute, São Paulo State University (UNESP), São José dos Campos 12247-004, Brazil.ORCID 0000-0002-4808-2362
Eder G FernandesImmunization Division-Centre of Epidemiology Surveillance of the São Paulo State Health Department, São Paulo 01246-000, Brazil.ORCID 0000-0001-6907-7063
José A CuminatoInstitute of Mathematics and Computer Science, São Paulo University (USP), São Carlos 13566-590, Brazil.ORCID 0000-0002-5461-6463
Universidade Estadual Paulista (Unesp) · BRUniversidade de São Paulo · BR

Funding

National Council for Scientific and Technological Development 164326/2020-0National Council for Scientific and Technological Development 316228/2021-4São Paulo Research Foundation 2013/07375-0São Paulo Research Foundation 2021/01305-6São Paulo Research Foundation 2021/03328-3São Paulo State University UNESP-PROPG
6 · The paper itself

Abstract

Considering the imminence of new SARS-CoV-2 variants and COVID-19 vaccine availability, it is essential to understand the impact of the disease on the most vulnerable groups and those at risk of death from the disease. To this end, the odds ratio (OR) for mortality and hospitalization was calculated for different groups of patients by applying an adjusted logistic regression model based on the following variables of interest: gender, booster vaccination, age group, and comorbidity occurrence. A massive number of data were extracted and compiled from official Brazilian government resources, which include all reported cases of hospitalizations and deaths associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Brazil during the "wave" of the Omicron variant (BA.1 substrain). Males (1.242; 95% CI 1.196-1.290) aged 60-79 (3.348; 95% CI 3.050-3.674) and 80 years or older (5.453; 95% CI 4.966-5.989), and hospitalized patients with comorbidities (1.418; 95% CI 1.355-1.483), were more likely to die. There was a reduction in the risk of death (0.907; 95% CI 0.866-0.951) among patients who had received the third dose of the anti-SARS-CoV-2 vaccine (booster). Additionally, this big data investigation has found statistical evidence that vaccination can support mitigation plans concerning the current scenario of COVID-19 in Brazil since the Omicron variant and its substrains are now prevalent across the entire country.

Indexed as

COVID-19hospitalizationmortalityOmicronrisk factors

Identifiers

PMID36290552
PMCPMC9598428
OpenAlexW4306920671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.